Introduction
Recent insight into the pathogenesis of avascular necrosis of the femoral head (ANFH) has not identified satisfactory methods to increase blood circulation in necrotic areas of the femoral head, to promote bone regeneration, or to prevent osteonecrosis. The rapid development of gene therapy technology is increasingly recognized as a new therapeutic option for the treatment of ANFH, especially through therapeutic neovascularization and bone formation. Among growth factors, vascular endothelial growth factor (VEGF) and bone morphogenetic protein (BMP) play important roles and have been extensively studied.
The VEGF family of growth factors is one of the most important cytokine families involved in angiogenesis. These factors promote the division of vascular endothelial cells and induce angiopoiesis. VEGF growth factors are essential for bone formation and repair during the bone regeneration process, which directly attracts endothelial cells and osteoclasts and enhances the differentiation of osteoblasts [1, 2] . BMP growth factors are the only signaling molecules that are individually sufficient for the induction of bone formation at orthotopic and heterotopic sites. They have defined roles in stimulating the proliferation and differentiation of mesenchymal and osteoprogenitor cells and have efficient bone induction activity [3, 4] . Because bone formation is a coordinated process involving the BMP and VEGF growth factors [5, 6] , orchestrating the timing with which these two factors are expressed may greatly enhance this process. Choosing a safe and effective vector system to transfer and correctly express a target gene during gene therapy is important. Several different strategies have been examined for the delivery of genes of interest, including the use of naked DNA or an adenoviral vector. Treatment with naked DNA is simple and well tolerated by the recipient organism due to its low toxicity and weak induction of immune responses. However, the transduction efficiency is significantly lower when compared with other methods. The adenovirus has frequently been the vector of choice for gene transfer because it is able to transduce a variety of cells with high efficiency. However, adenoviral vectors have major limitations, including a lack of sustained expression, the antigenicity of viral proteins that are targeted by both humoral immunity and cytotoxic T lymphocytes, and possible toxicity at high doses. However, there are many inherent features of the adeno-associated virus system that make it an attractive option as a human viral vector. AAV is a non-pathogenic, defective human parvovirus that requires the presence of a helper virus, such as adenovirus or herpes virus, for productive infection [7, 8] . Other advantages of this vector system include its low immunogenicity, its ability to transduce both dividing and non-dividing cells, the potential to integrate into specific sites, its ability to achieve long-term gene expression (even in vivo), and its broad tropism, allowing for the efficient transduction of diverse organs [9] . These features make AAV attractive and efficient for gene transfer in vitro and local injection in vivo.
To enhance neovascularization and bone regeneration during osteonecrosis therapy, we constructed adeno-associated viruses co-expressing hVEGF 165 and hBMP-7 (rAAV-VEGF 165 -IRES-BMP-7) and detected their effect on gene expression and biological activity in vitro and in vivo. These data demonstrate the synergistic action of these two genes and may provide a new therapeutic option for ANFH.
Materials and methods

Materials and reagents
The rAAV-hVEGF 165 -IRES-hBMP-7 (AAV-VEGF/BMP), rAAVhVEGF 165 -GFP (AAV-VEGF), rAAV-hBMP-7-GFP (AAV-BMP), and rAAV-IRES-GFP (AAV-GFP) plasmids were constructed by Dr Xiang-hui HUANG. Human embryonic kidney cells-293 (HEK-293) and human umbilical vein endothelial cells (HUVECs) were obtained from the Department of Orthopedic Surgery in the Second Affiliated Hospital of Xi'an Jiaotong University. Male New Zealand rabbits (two months old, weighing 2.0-3.0 kg) were obtained from the experimental animal center of Xi'an Jiao Tong University. All animal protocols followed the recommendations and guidelines of the National Institutes of Health and were approved by the Xi'an Jiao Tong University Animal Care and Use Committee. The AAV helper-free system was obtained from Stratagene (La Jolla, CA, USA). A schematic representation of the structure of the plasmids in the AAV Helper Free System is provided in Figure 1A .
rAAV vector production The construction of the rAAV-hVEGF 165 -IRES-hBMP-7 (AAV-VEGF/BMP), rAAV-hVEGF 165 -GFP (AAV-VEGF), rAAV- www.chinaphar.com Zhang C et al Acta Pharmacologica Sinica npg hBMP-7-GFP (AAV-BMP), and rAAV-IRES-GFP (AAV-GFP) vectors was carried out as previously described [10] . The structure of the pAAV-hVEGF 165 -IRES-hBMP-7 vector is shown in Figure 1B . IRES sequences were incorporated into the pAAV MCS to construct a bicistronic vector with two multiple cloning sites. Then, the hVEGF 165 (Pubmed NM-003376) and hBMP-7 (Pubmed NM-001719) genes were inserted into the upstream and downstream MCS, respectively. The length of the bicistronic frame is 2.5 kb, which is within the capacity of the vector. The AAV helper-free system was used to generate recombinant AAV. HEK-293 cells were cultured in H-DMEM supplemented with 10% fetal bovine serum containing 20 mg/mL penicillin-streptomycin and incubated with 5% CO 2 at 37 o C. The AAV vector was co-transfected with the pAAVhelper and pAAV-RC vectors into HEK 293 cells by a calcium phosphate method according to the manufacturer's instructions (Invitrogen, Carlsbad, CA, USA). A primary virus stock was collected 72 h after transfection and further concentrated and purified by chloroform/PEG8000 protocols [11] . The recombinant adeno-associated virus had a titer of 5.5×10
11 vp/mL.
Rabbit bone marrow-derived mesenchymal stem cells (BMSC) culture and rAAV infection in vitro
Male New Zealand rabbits were used to obtain rabbit BMSCs. The cells were harvested by gently flushing the tibiae and femora with L-DMEM. Density gradient centrifugation and adherent screening methods were used to isolate BMSCs as previously described [12] . The cells were cultured in L-DMEM supplemented with 10% fetal bovine serum containing 20 mg/mL penicillin-streptomycin and incubated with 5% CO 2 at 37 o C. Following the 3rd passage, BMSCs (5×l0 4 cells/well) were seeded onto 24-well plates 24 h before rAAV infection. By taking into account the cytopathogenic effect, infection efficiency, and cost of recombinant virus, we determined that the best multiplication of infection (MOI) for infecting rabbit BMSCs with rAAV was 5×10 4 vp/cell. The four rAAV virus variants were introduced into BMSCs using this MOI. Cells were incubated as above and were swirled gently at 30-min intervals. One hour later, the medium was replaced with L-DMEM supplemented with 10% fetal bovine serum. Medium was then completely replaced every three days.
Rabbit hind limb ischemia model and rAAV infection in vivo
Male New Zealand rabbits were kept under specific pathogen free conditions and supplied with sterile food and acidified water. The hind limb ischemia model was developed as described previously [13] . Rabbits were anesthetized with an intraperitoneal injection of sodium pentobarbital (50 mg/kg). Under a surgical microscope, a vertical longitudinal incision was made in the right hind limb. The right femoral arteries were separated from the origin of the external iliac artery, ligated, and completely excised. Immediately after ligation of the femoral artery, the four rAAV virus variants were each injected into five different sites [14] on the three major thigh muscles of each rabbit (5.5×10
11 vp/20 µL per site), including the adductor (two sites), the quadriceps (two sites), and the semimembranous (one site) muscles. Subsequently, the skin was sutured. After surgery, all animals were housed under standard conditions (temperature: 21±1 °C; humidity: 55%-60%) with food and water continuously available. The hind limbs were mobilized without any fixation. To prevent infection, animals received prophylactic injections of gentamicin (0.03 mg·kg -1 ·d -1 , im) within 3 days after surgery. Rabbits were sacrificed at various time points post-injection to characterize gene expression efficiency and the effects on angiopoiesis and bone regeneration in vivo. Each group contained 30 rabbits and was divided into four experimental subgroups: group A (n=6) was examined at week 2 for GFP expression (n=3) and immunoblotting (n=3), group B (n=6) at week 4 for GFP expression (n=3) and immunoblotting (n=3), group C (n=9) at week 6 for GFP expression (n=3), immunoblotting (n=3), and ELISA (n=3), and group D (n=9) at week 8 for GFP expression (n=3) and for blood flow measurement, X-ray radiography, and immunohistochemistry (n=6).
Reporter gene (GFP) expression in vitro and in vivo
Following 3, 7, 14, and 28 days of infection with AAV-GFP virus in vitro, the expression of GFP protein was observed by inverted fluorescence microscopy. At 2, 4, 6, and 8 weeks post-injection in vivo, the muscles injected with the AAV-GFP virus were sliced by the frozen section method and the expression of the GFP protein was observed as above. Each assay was performed in triplicate.
Preparation of culture medium and assessment of VEGF 165 and BMP-7 gene expression Total cellular RNA was isolated at 1, 2, 3, 7, 14, 21, and 28 days following infection with the AAV-GFP, AAV-VEGF, AAV-BMP or AAV-VEGF/BMP viruses using TRIzol Reagent (Invitrogen). Extracted RNA was treated with DNase I (Takara, Tokyo, Japan) to eliminate DNA contamination, and first-strand cDNA was synthesized with random hexamer primers using the reverse first-strand cDNA synthesis kit from MBI Fermentas (Glen Burnie, MD, USA). PCR was performed to amplify humanVEGF 165 (forward primer 5'-CCATCGA-TATGAACTTTCTGCTGTCTTG-3'; reverse primer 5'-CG-GAATTCTCACCGCCTCGGCTTGTC-3') and BMP-7 (forward primer 5'-GGCCGGATCCATGCACGTGCGCTCACTGCG-3'; reverse primer 5'-GGCCGTCGACCTAGTGGCAGCCA-CAG-3'). β-actin (forward primer 5'-GAGGGAAATCGT-GCGTGAC-3'; reverse primer 5'-TAGGAGCCAGGGCAG-TAATCT-3') was detected by RT-PCR as an internal control. PCR was performed using the following program: 94 °C for 3 min for one cycle and 35 cycles at 94 °C for 30 s, 55 °C for 30 s, and 72 °C for 45 s. The PCR products were electrophoresed on ethidium bromide-stained 2.0% agarose gels. Each assay was performed in triplicate.
Muscle extract preparation and assessment of VEGF 165 and BMP-7 gene expression At 2, 4, and 6 weeks following injection with the AAV-GFP, AAV-VEGF, AAV-BMP, or AAV-VEGF/BMP viruses, 
Angiogenic and osteogenic in vitro assays
Tube formation assay HUVECs were cultured as previously described [15] . Basement membrane matrigel matrix (BD, Bedford, MA, USA) was diluted by serum-free medium, added to a 24-well plate, and incubated at 37 °C for 30 min to allow solidification to occur. HUVECs (5×10 4 cells/well) were seeded on the matrigel and fresh L-DMEM medium supplemented with 10% FBS was added. Next, 1 mL of culture supernatant was harvested from the AAV-GFP, AAV-VEGF, AAV-BMP, or AAV-VEGF/BMP groups 14 days post-infection and added to the 24-well plate. The plate was then incubated at 37 o C with 5% CO 2 for 12 h. The images of tube formation were captured under a light microscope from three random fields, and quantification of the tubes was analyzed by image processing software (Media Cybernetics, USA) to assess the biological activity of VEGF in vitro.
Mineralization assay
BMSCs were infected with the four virus groups above. The cells were then cultured in L-DMEM supplemented with 10% fetal bovine serum containing 20 mg/mL penicillinstreptomycin with 5% CO 2 at 37 °C (the culture medium did not contain osteogenic induction factors, such as ascorbic acid, β-glycerophosphate, or dexamethasone). Mineralization effects were detected by von Kossa and alizarin red (AZR) staining [16] for calcium deposits 4 weeks post-infection and observed using an inverted phase contrast microscope. The images of mineral nodules were captured under a light microscope from three random fields, and quantification of the mineral nodules was analyzed by image processing software to assess the biological activity of BMP in vitro.
Blood flow measurement and orthotopic bone formation in vivo Eight weeks after injection, rabbits in the four groups were anesthetized with an intraperitoneal injection of sodium pentobarbital (50 mg/kg). Blood flow in the anterior tibial artery of ischemic and normal hind limbs was measured at rest with an Aspen Advanced Doppler ultrasound device from Acuson (Siemens Medical Solutions, Mountain View, CA, USA) using a perivascular flow probe and calculated by the inlay automatic processing software. The data were expressed as a percentage of the contralateral limbs. Three separate measurements were performed for each rabbit at every time point and the results were averaged. In addition, rabbits in the four groups were subjected to X-ray radiography to assess orthotopic bone formation.
Histological assessment
Eight weeks after injection, thigh muscle tissue sections of ischemic limbs from the four groups were harvested and fixed in 10% neutral-buffered formalin. To identify the proliferation of capillary endothelial cells, tissue sections were immunostained for CD34. The monoclonal antibody against CD34 was applied at a 1:500 dilution after blocking with 1% normal bovine serum. Subsequent incubation with biotinylated horse anti-mouse IgG and an ABC Elite kit (Santa Cruz) was performed. The number of CD34-positive vessels was counted at a magnification of 200×, and twenty fields from each typical slide were counted (mean number of capillaries per square millimeter). To assess orthotopic bone formation, the slides were stained by von Kossa staining to detect mineralization.
Statistical analysis
The results are reported as means±standard deviation. The normality of the data distribution was assessed with the Shapiro-Wilk (W) test. ANOVA followed by the Fisher's test was conducted to assess differences among treatment groups. Statistical significance was set at a P-value less than or equal to 0.05. The SPSS mathematical statistics software used for this analysis was purchased from SPSS Inc (version 8; SPSS Inc, Chicago, IL, USA).
Results
Animal condition after rAAV infection
There were no symptoms of local or systemic toxicity after rAAV infection. In the region of the injection sites, no inflammatory reaction, such as rubeosis, engorgement, or abscessus, was observed. The activities of all animals were normal. There was no systemic toxicity, such as nutation, instability of gait, anhelation, retardation, cyanosis, or convulsion. No animals died before the end of the experiments.
GFP gene expression
In vitro: GFP protein expression could be detected on the third day post-infection. However, the efficiency and density of infection were unstable. The expression of GFP protein increased from the 7th day and could be detected at 28 days post-infection (Figures 2A, 2B ). In vivo: With prolonged infection time, GFP protein expression increased from the 4th week and could be detected at 8 weeks post-infection ( Figures 2C,  2D ).
Efficient genes expression of hVEGF 165 and hBMP-7
To confirm hVEGF 165 and hBMP-7 gene expression in vitro, RT-PCR assays were performed. As shown in Figure  3A -3D, the sizes of the PCR products for VEGF 165 , BMP-7, www.chinaphar.com Zhang C et al Acta Pharmacologica Sinica npg and β-actin were 600 bp, 1300 bp, and 340 bp, respectively. With prolonged infection time, the intensity of the VEGF 165 and BMP-7 bands increased in the AAV-VEGF/BMP group. Together, these data demonstrate that VEGF 165 was expressed in the AAV-VEGF and AAV-VEGF/BMP groups but not in the AAV-BMP and AAV-GFP groups and that BMP-7 was expressed in the AAV-BMP and AAV-VEGF/BMP groups but not in the AAV-VEGF and AAV-GFP groups. Protein expression of 2, 4, and 6 weeks following injection with AAV-VEGF/ BMPin vivo is shown in Figure 3E -3H . Expression of the VEGF 165 and BMP-7 proteins was visualized by Western blot analysis. Strong staining at the expected molecular weights of 23 kDa (hVEGF 165 ), 55 kDa (hBMP-7), and 43 kDa (β-actin) was observed. With prolonged infection time, the intensity of the VEGF 165 and BMP-7 bands increased. These data demonstrate that VEGF 165 was expressed in the AAV-VEGF and AAV-VEGF/BMP groups but not in the AAV-BMP and AAV-GFP groups and that BMP-7 was expressed in the AAV-BMP and AAV-VEGF/BMP groups but not in the AAV-VEGF and AAV-GFP groups. As shown in Figure 3I , 3J, the production of hVEGF 165 and hBMP-7 was quantified in relevant muscle extracts 6 weeks post-injection. The average amounts of hVEGF 165 protein in the AAV-VEGF/BMP and AAV-VEGF groups were significantly higher than those in the AAV-GFP and AAV-BMP groups (P<0.05, n=30) . The average amounts of hBMP-7 protein in the AAV-VEGF/BMP and AAV-BMP groups were significantly higher than those in the AAV-GFP and AAV-VEGF groups (P<0.05, n=30).
Biological activity of hVEGF 165 and hBMP-7 in vitro
As shown in Figure 4A , hVEGF 165 secreted from BMSCs in the AAV-VEGF/BMP group enhanced HUVEC migration, proliferation, and tube formation in comparison with the other three groups. The number of tubes in the AAV-VEGF/BMP group was significantly higher than that in the AAV-GFP and AAV-BMP groups. However, there was no statistical difference between the AAV-VEGF/BMP group and the AAV-VEGF group ( Figure 4B ). In addition, the mineralization effect of hBMP-7 was detected by von Kossa ( Figure 5A ) and alizarin red staining ( Figure 5B ). The AAV-VEGF/BMP group displayed stronger osteogenic activity than all the other groups. The number of mineralized nodules in the AAV-VEGF/BMP group was significantly higher than that in the AAV-GFP and AAV-VEGF groups. However, there was no statistical difference between the AAV-VEGF/BMP group and the AAV-BMP group ( Figure 5C ).
Biological activity of hVEGF 165 and hBMP-7 in vivo
The ability of hVEGF 165 and hBMP-7 to induce tube formation and mineralization in vitro correlated well with their in vivo role in neovascularization and bone regeneration. Blood flow in the anterior tibial artery of ischemic and normal hind As shown in Figure 6 , the ratio of mean ischemic/normal blood flow in the AAV-VEGF/BMP group was highest when compared with the AAV-GFP, AAV-VEGF, and AAV-BMP groups. However, there was no statistical difference between the AAV-VEGF/ BMP group and the AAV-VEGF group. In addition, rabbits in the four groups were subjected to X-ray radiography to assess the bone regeneration activity of hBMP-7 in vivo. As shown in Figure 7 , orthotopic ossification was radiographically evident in the AAV-VEGF/BMP group eight weeks post-injection. In contrast, no radiographic evidence of bone formation was observed in the AAV-GFP group or the AAV-VEGF group.
Histological assessment
To further assess vascularity in rAAV-infected muscle, immunostaining for CD34, a marker of vessel endothelial cells, was performed to detect the number of capillaries. As shown in Figure 8A , muscle from the AAV-VEGF/BMP group contained significantly more capillaries when compared with the other three groups at 8 weeks post-injection. The mean density of capillaries in the AAV-VEGF/BMP group was significantly higher than that in the AAV-GFP and AAV-BMP groups. However, there was no statistical difference between the AAV-VEGF/BMP group and the AAV-VEGF group (Figure 8C ). To analyze bone formation, von Kossa staining was adopted to assess calcium deposits 8 weeks post-injection. As shown in Figure 8B , calcium deposits stained black. The osteogenic ability of the AAV-VEGF/BMP group was significantly enhanced compared with that found in the other three groups.
Discussion
The packaging capacity of the rAAV vector (5 kb, including the inverted terminal repeats) remains one of its primary limitations in terms of gene delivery. However, substantial progress has recently been made to overcome this restriction. Among the several different strategies to co-express multiple npg genes, the incorporation of an IRES into this gene therapy vector represents one of the more promising strategies [17] [18] [19] . The IRES functions as a ribosome landing pad for the efficient internal initiation of translation, ensuring coordinated expression of several genes. The IRES initiates ribosome binding and translation in the absence of a 5'CAP, thus overcoming the main disadvantage of traditional strategies that express two different genes. This characteristic is especially useful for AAV production due to the packaging size limitation imposed by the AAV vectors. In our current study, an IRES sequence was incorporated into the pAAV MCS to construct a bicistronic vector. Then, the hVEGF 165 and hBMP-7 genes were inserted upstream and downstream of the MCS, located on either side of the IRES to create a bicistronic frame of 2.5 kb in length, which is within the capacity of the vector. In our study, we reveal that AAV-mediated hVEGF 165 and hBMP-7 gene transfer in vitro and in vivo induces the expression and secretion of the hVEGF 165 and hBMP-7 proteins. These results demonstrate that the IRES sequence may be a superior strategy for co-expressing multiple genes in rAAVs.
An important characteristic of rAAV is that when the host cell is infected with rAAV, the efficiency of infection cannot immediately be determined. The expression of the gene of interest will not be activated until the double-stranded nucleic acid version of the virus has been synthesized by DNA synthetase. The time required for this to occur may be several days, weeks, or months and is dependent on the infection surrounding the host cells [20] . For this reason, it is essential to detect the timing of gene expression in vitro and in vivo. The results of GFP expression and RT-PCR analysis in vitro and of Western blotting and ELISA assays in vivo revealed expression of the genes of interest, indicating that the rAAV vector has superior gene expressing ability.
The key aim of gene therapy for osteonecrosis disease is bone and vessel regeneration. Bone restoration is a compli- [2, 4, 18, 20, 21] . BMPs are the only signaling molecules that can singly induce de novo bone formation at orthotopic and heterotopic sites. BMPs have discrete effects on the proliferation and differentiation of mesenchymal cells and osteoprogenitor cells and also have efficient bone induction activity [3, 22] . Thus, orchestrating the timing of expression of these two factors may greatly enhance this process.
We performed angiogenic and osteogenic assays to identify the biological effect of VEGF 165 and BMP-7 in vitro and in vivo. The results indicated that at the dosage used, the rAAVhVEGF 165 -IRES-hBMP-7 virus had excellent biological activity and could properly mediate biological activity both in vitro and in vivo. However, one interesting finding of our study was that VEGF alone is not sufficient to improve bone formation and that BMP alone is not sufficient to improve vessel regeneration. We conclude that these findings were not due to improper dosage, but reflect the fact that expression of VEGF or BMP alone is not sufficient to initiate the cascade of bone formation or vessel regeneration, respectively. These findings also demonstrate that orchestrating the expression of these two factors is essential for effective therapy of osteonecrosis disease. An additional interesting finding in our studies was that there was no statistical difference between the AAV-VEGF/ BMP group and the AAV-VEGF group in terms of angiogenesis. Similarly, there was no statistical difference between the AAV-VEGF/BMP group and the AAV-BMP group in terms of bone formation. We conclude that there may be a requirement for the proper ratio of VEGF to BMP. As shown by a previous study [23] , the proper ratio of VEGF to BMP is critical to ensure synergistic effects. In addition, the unequal expression of the VEGF and BMP genes located upstream and downstream of the IRES may be responsible [24] . Thus, comparison of the expression of genes located upstream and downstream of the IRES and the identification of the best ratio of VEGF and BMP for treatment of osteonecrosis will be imperative in future experiments.
In summary, we used rAAV as a gene transduction system by successfully inserting the VEGF 165 and BMP-7 genes in this vector, allowing them to be efficiently and stably co-expressed. The VEGF 165 and BMP-7 proteins that were expressed from the rAAV-hVEGF 165 -IRES-hBMP-7 vector enhanced angiogenesis and bone regeneration in vitro and in vivo. Our experiments establish a foundation for investigating the synergistic biological effects of VEGF 165 and BMP-7 in vitro and in vivo and provide theoretical support for gene therapy of ANFH with our recombinant virus. 
